IL292213A - Combination anti-tumor therapy including anti-cd19 antibody and gamma delta t cells - Google Patents
Combination anti-tumor therapy including anti-cd19 antibody and gamma delta t cellsInfo
- Publication number
- IL292213A IL292213A IL292213A IL29221322A IL292213A IL 292213 A IL292213 A IL 292213A IL 292213 A IL292213 A IL 292213A IL 29221322 A IL29221322 A IL 29221322A IL 292213 A IL292213 A IL 292213A
- Authority
- IL
- Israel
- Prior art keywords
- cells
- antibody
- antibody fragment
- administered
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19206479 | 2019-10-31 | ||
| PCT/EP2020/080494 WO2021084063A1 (en) | 2019-10-31 | 2020-10-30 | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292213A true IL292213A (en) | 2022-06-01 |
Family
ID=68424789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292213A IL292213A (en) | 2019-10-31 | 2020-10-30 | Combination anti-tumor therapy including anti-cd19 antibody and gamma delta t cells |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210130461A1 (https=) |
| EP (2) | EP4706673A2 (https=) |
| JP (2) | JP7688025B2 (https=) |
| KR (1) | KR20220116154A (https=) |
| CN (1) | CN115151565A (https=) |
| AU (1) | AU2020372646A1 (https=) |
| DK (1) | DK4051710T3 (https=) |
| ES (1) | ES3062643T3 (https=) |
| FI (1) | FI4051710T3 (https=) |
| HR (1) | HRP20251630T1 (https=) |
| IL (1) | IL292213A (https=) |
| LT (1) | LT4051710T (https=) |
| MA (1) | MA69251B1 (https=) |
| MD (1) | MD4051710T2 (https=) |
| MX (1) | MX2022005033A (https=) |
| PH (1) | PH12022551009A1 (https=) |
| PL (1) | PL4051710T3 (https=) |
| PT (1) | PT4051710T (https=) |
| RS (1) | RS67602B1 (https=) |
| SI (1) | SI4051710T1 (https=) |
| SM (1) | SMT202600082T1 (https=) |
| TW (1) | TWI883067B (https=) |
| WO (1) | WO2021084063A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767063C2 (ru) | 2015-08-21 | 2022-03-16 | МорфоСис АГ | Комбинации и их использование |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| KR102617497B1 (ko) | 2022-09-15 | 2023-12-27 | 주식회사 엘지에너지솔루션 | 음극용 자성 정렬 장치 및 이를 이용한 음극의 제조방법 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| CA2534639C (en) | 2003-07-31 | 2013-07-30 | Immunomedics, Inc. | Anti-cd19 antibodies |
| CA2611814A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| ES2365046T3 (es) | 2005-12-30 | 2011-09-21 | Merck Patent Gmbh | Anticuerpos anti-cd19 con inmunogenicidad reducida. |
| PL2383297T3 (pl) | 2006-08-14 | 2013-06-28 | Xencor Inc | Zoptymalizowane przeciwciała ukierunkowane na CD19 |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
| EP2409712A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile |
| EP2409993A1 (en) | 2010-07-19 | 2012-01-25 | International-Drug-Development-Biotech | Anti-CD19 antibody having ADCC function with improved glycosylation profile |
| US8940707B2 (en) | 2010-10-28 | 2015-01-27 | Viropharma Incorporated | Maribavir isomers, compositions, methods of making and methods of using |
| EP2524929A1 (en) | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| PT2710123T (pt) | 2011-05-19 | 2017-10-13 | Inst De Medicina Molecular | Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos |
| AU2015277516A1 (en) * | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| IL297773B2 (en) | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| LT3302550T (lt) * | 2015-05-26 | 2019-11-11 | Morphosys Ag | Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas |
| AU2016274633B2 (en) | 2015-06-09 | 2022-04-21 | Gammadelta Therapeutics Ltd | Methods for the production of TCR gamma delta+ T cells |
| WO2017072367A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Research Technology Limited | EXPANSION OF NON-HAEMATOPOIETIC TISSUE-RESIDENT γδ T CELLS AND USES OF THESE CELLS |
| US11299708B2 (en) | 2016-05-12 | 2022-04-12 | Adicet Bio, Inc. | Methods for selective expansion of γδ T-cell populations and compositions thereof |
| WO2018002031A1 (en) | 2016-06-27 | 2018-01-04 | Morphosys Ag | Anti-cd19 antibody formulations |
| WO2018081648A2 (en) * | 2016-10-29 | 2018-05-03 | Genentech, Inc. | Anti-mic antibidies and methods of use |
| GB201707048D0 (en) | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
-
2020
- 2020-10-30 CN CN202080090109.2A patent/CN115151565A/zh active Pending
- 2020-10-30 PL PL20800121.4T patent/PL4051710T3/pl unknown
- 2020-10-30 JP JP2022525535A patent/JP7688025B2/ja active Active
- 2020-10-30 FI FIEP20800121.4T patent/FI4051710T3/fi active
- 2020-10-30 AU AU2020372646A patent/AU2020372646A1/en active Pending
- 2020-10-30 MX MX2022005033A patent/MX2022005033A/es unknown
- 2020-10-30 SM SM20260082T patent/SMT202600082T1/it unknown
- 2020-10-30 EP EP25217971.8A patent/EP4706673A2/en active Pending
- 2020-10-30 EP EP20800121.4A patent/EP4051710B1/en active Active
- 2020-10-30 PT PT208001214T patent/PT4051710T/pt unknown
- 2020-10-30 KR KR1020227018073A patent/KR20220116154A/ko active Pending
- 2020-10-30 LT LTEPPCT/EP2020/080494T patent/LT4051710T/lt unknown
- 2020-10-30 WO PCT/EP2020/080494 patent/WO2021084063A1/en not_active Ceased
- 2020-10-30 SI SI202030692T patent/SI4051710T1/sl unknown
- 2020-10-30 RS RS20251350A patent/RS67602B1/sr unknown
- 2020-10-30 US US17/084,783 patent/US20210130461A1/en active Pending
- 2020-10-30 IL IL292213A patent/IL292213A/en unknown
- 2020-10-30 MD MDE20220968T patent/MD4051710T2/ro unknown
- 2020-10-30 TW TW109137982A patent/TWI883067B/zh active
- 2020-10-30 ES ES20800121T patent/ES3062643T3/es active Active
- 2020-10-30 DK DK20800121.4T patent/DK4051710T3/da active
- 2020-10-30 MA MA69251A patent/MA69251B1/fr unknown
- 2020-10-30 PH PH1/2022/551009A patent/PH12022551009A1/en unknown
- 2020-10-30 HR HRP20251630TT patent/HRP20251630T1/hr unknown
-
2025
- 2025-05-22 JP JP2025085318A patent/JP2025134705A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS67602B1 (sr) | 2026-01-30 |
| SI4051710T1 (sl) | 2026-01-30 |
| EP4051710B1 (en) | 2025-11-26 |
| JP7688025B2 (ja) | 2025-06-03 |
| LT4051710T (lt) | 2026-03-10 |
| MA69251B1 (fr) | 2025-12-31 |
| DK4051710T3 (da) | 2025-12-15 |
| US20210130461A1 (en) | 2021-05-06 |
| PL4051710T3 (pl) | 2026-04-20 |
| FI4051710T3 (fi) | 2026-01-12 |
| EP4051710A1 (en) | 2022-09-07 |
| TWI883067B (zh) | 2025-05-11 |
| WO2021084063A1 (en) | 2021-05-06 |
| CA3158984A1 (en) | 2021-05-06 |
| TW202131949A (zh) | 2021-09-01 |
| AU2020372646A1 (en) | 2022-05-12 |
| PT4051710T (pt) | 2026-02-09 |
| EP4706673A2 (en) | 2026-03-11 |
| KR20220116154A (ko) | 2022-08-22 |
| PH12022551009A1 (en) | 2023-03-20 |
| HRP20251630T1 (hr) | 2026-02-13 |
| JP2022554324A (ja) | 2022-12-28 |
| MD4051710T2 (ro) | 2026-04-30 |
| JP2025134705A (ja) | 2025-09-17 |
| MX2022005033A (es) | 2022-09-09 |
| TW202547555A (zh) | 2025-12-16 |
| CN115151565A (zh) | 2022-10-04 |
| SMT202600082T1 (it) | 2026-03-09 |
| ES3062643T3 (en) | 2026-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4051710B1 (en) | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells | |
| CA2994822C (en) | Near infrared photoimmunotherapy (nir-pit) of suppressor cells to treat cancer | |
| US20130058921A1 (en) | Use of autologous effector cells and antibodies for treatment of multiple myeloma | |
| JP2022503685A (ja) | 抗ｃｄ１９抗体及びナチュラルキラー細胞を含む、腫瘍を治療する薬学的組み合わせ | |
| TW201617093A (zh) | 對抗ｐｄ－１及ｐｄ－ｌ１之拮抗劑與輻射療法組合之治療方法 | |
| JP2025175307A (ja) | 逐次抗ｃｄ１９治療 | |
| US20230014026A1 (en) | Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune Checkpoint | |
| IL292181A (en) | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma | |
| EP3491023A1 (en) | Cancer and b-cell related disease therapy | |
| CA3158984C (en) | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells | |
| TWI922280B (zh) | 包含抗CD19抗體及γδ T細胞之抗腫瘤組合療法 | |
| EA050676B1 (ru) | Противоопухолевая комбинированная терапия, включающая антитело к cd19 и гамма-дельта т-клетки | |
| US20240190965A1 (en) | Targeting anti-human pd 1h/vista to treat hematologic disorders | |
| AU2020209425B2 (en) | Antibody | |
| KR20250060146A (ko) | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 | |
| CA3126869A1 (en) | Antibody |